Positive and negative breast cancer screening refers to the molecular expression in immunohistochemistry of tumor pathology examination after breast cancer surgery, mainly including estrogen receptor, progesterone receptor and human epidermal growth factor-2 receptor. The difference between positive and negative is mainly reflected in the choice of treatment and prognosis.
1. Choice of treatment: If the hormone receptor is positive, endocrine therapy can be chosen, either tamoxifen or third-generation aromatase inhibitors to inhibit estrogen production, or ovariectomy.
Chemotherapy is usually chosen for negative patients. Human epidermal growth factor-2 receptor-positive patients require additional targeted therapy, while negative patients require only chemotherapy or endocrine therapy.
2. Prognosis: Patients who are positive for all three receptors have a good prognosis after surgery and may even survive for more than 5 years. For patients who are negative for all three receptors, the prognosis is poorer, and they are even prone to recurrence within 1 to 2 years.
Pay attention to a balanced diet with high vitamins and low fat. It is recommended to seek medical treatment in time so as not to miss the disease.